Abstract
Hypertension is a known risk factor for clear cell renal cell carcinoma (ccRCC), yet the underlying mechanisms remain elusive. Studies have confirmed that the renin-angiotensin system (RAS) plays a role beyond regulating blood pressure, influencing various aspects of tumor development and metastasis. Generally, activation of the angiotensin-converting enzyme (ACE)/angiotensin II (Ang II)/angiotensin type 1 receptor (AT1R) axis elevates blood pressure and promotes tumor progression, while the activation of the angiotensin-converting enzyme 2 (ACE2)/[Ang-(1-7)]/Mas receptor (MasR) axis antagonizes these effects. Consequently, many cardiovascular drugs targeting the RAS may possess both hypotensive and antitumor properties. However, the role of RAS in ccRCC is controversial. This review provides an overview of the RAS, highlights research advances in RAS for ccRCC, elucidates the current status of RAS-targeted drugs in the treatment of ccRCC, and discusses the current challenges and future research directions in this field. In conclusion, the upregulation of other effector peptides and the activation of receptors in the RAS, apart from ACE2, may expedite ccRCC progression. Therefore, careful consideration is needed when using relevant drugs in ccRCC patients with hypertension.
Introduction
Hypertension is a well-established risk factor for clear cell renal cell carcinoma (ccRCC), the most common form of kidney cancer, with hypertensive individuals facing a 1.2 to 1.71 times higher risk of developing the disease. Because the Renin-Angiotensin System (RAS) is the primary hormonal network governing blood pressure, researchers have long suspected it plays a critical role in renal oncogenesis. This review explores the complex and often contradictory role of the RAS in ccRCC, highlighting how its various signaling axes act as a "double-edged sword" that can either suppress or accelerate tumor progression and metastasis.
The Dual-Axis Mechanism of RAS
The RAS traditionally operates via two opposing pathways. The ACE/Ang II/AT1R axis is typically associated with inflammation, oxidative stress, and the promotion of tumor growth. In contrast, the ACE2/Ang-(1-7)/MasR axis generally acts as a physiological brake, providing vascular protection and anti-tumor effects. In many cancers, these two axes maintain a balance that influences the tumor microenvironment (TME).
Clinical data indicates that high ACE2 expression is consistently linked to improved 15-year overall survival rates in ccRCC patients, suggesting its role as a protective factor. However, the RAS also influences the TME by modulating macrophage phenotypes and promoting "Vasculogenic Mimicry"—a process where aggressive cancer cells form their own fluid-conducting channels, bypassing the need for traditional angiogenesis.
The ccRCC Paradox: Deviations from the Standard Model
While the dual-axis model holds true for many malignancies, ccRCC presents unique contradictions. Surprisingly, some studies suggest that in ccRCC, the normally "protective" Ang-(1-7) peptide might actually promote cell migration and invasion via the AKT signaling pathway. This contradicts its behavior in many other cancer types and suggests that RAS-targeted therapies must be tailored specifically to the kidney.
Furthermore, clinical observations show that both ACE and ACE2 are often downregulated in ccRCC compared to healthy kidney tissue. This suggests that the loss of normal RAS regulation, rather than just the overactivation of a single pathway, may be a primary driver of malignancy in the renal context.
Clinical Implications and Therapeutic Potential
The therapeutic potential of RAS inhibitors in ccRCC remains a subject of intense study. In animal models using 786-O and Caki-1 ccRCC cell lines, the Angiotensin Receptor Blocker (ARB) telmisartan significantly reduced tumor growth by inducing tumor necrosis and inhibiting VEGF, a key protein for blood vessel growth.
Despite these promising laboratory results, clinical evidence is mixed. While observational studies suggest that RAS inhibitors may lower cancer incidence (RR = 0.82), randomized controlled trials (RCTs) have yet to confirm a significant therapeutic effect (RR = 1.00). This gap between "real-world" observations and controlled clinical outcomes highlights the need for more nuanced research into patient selection and drug timing.
Challenges and Future Directions
Several hurdles remain in translating RAS research into clinical practice for ccRCC:
- Inconsistency: The effects of RAS components vary significantly between different cell lines and animal models, making it difficult to establish a universal therapeutic rule.
- Targeted Delivery: Systemic RAS inhibitors affect the entire body. Future research should focus on targeted drug delivery, such as using engineered exosomes to deliver RAS-modulating agents directly to the tumor site to minimize systemic side effects.
- Lifestyle and Non-ACE Effectors: Chronic stress activates the RAS and may accelerate tumor growth, while exercise might provide a salutary regulatory influence. Additionally, other metabolites like Bradykinin and the (pro)renin receptor (PRR) are emerging as potential players that require further investigation.
Conclusion
In ccRCC, the activation of RAS components—with the notable exception of ACE2—may facilitate tumor progression and metastasis. This unexpected finding suggests that clinicians should exercise caution when prescribing RAS inhibitors to ccRCC patients with hypertension. A deeper understanding of these mechanisms is crucial for informing clinical management and guiding the development of novel, targeted therapeutic strategies.
Summary updated